Literature DB >> 19005060

Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity.

Lin Wai Hung1, Giuseppe D Ciccotosto, Eleni Giannakis, Deborah J Tew, Keyla Perez, Colin L Masters, Roberto Cappai, John D Wade, Kevin J Barnham.   

Abstract

Alzheimer's disease is an age-related neurodegenerative disorder with its toxicity linked to the generation of amyloid-beta peptide (Abeta). Within the Abeta sequence, there is a systemic repeat of a GxxxG motif, which theoretical studies have suggested may be involved in both peptide aggregation and membrane perturbation, processes that have been implicated in Abeta toxicity. We synthesized modified Abeta peptides, substituting glycine for leucine residues within the GxxxG repeat motif (GSL peptides). These GSL peptides undergo beta-sheet and fibril formation at an increased rate compared with wild-type Abeta. The accelerated rate of amyloid fibril formation resulted in a decrease in the presence of small soluble oligomers such as dimeric and trimeric forms of Abeta in solution, as detected by mass spectrometry. This reduction in the presence of small soluble oligomers resulted in reduced binding to lipid membranes and attenuated toxicity for the GSL peptides. The potential role that dimer and trimer species binding to lipid plays in Abeta toxicity was further highlighted when it was observed that annexin V, a protein that inhibits Abeta toxicity, specifically inhibited Abeta dimers from binding to lipid membranes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005060      PMCID: PMC6671645          DOI: 10.1523/JNEUROSCI.3916-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  78 in total

1.  Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Gaëlle Naert; Serge Rivest
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

2.  Potential therapeutic system for Alzheimer's disease: removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients.

Authors:  Masao Kato; Kazunori Kawaguchi; Sigeru Nakai; Kazutaka Murakami; Hideo Hori; Atsushi Ohashi; Yoshiyuki Hiki; Shinji Ito; Yasunobu Shimano; Nobuo Suzuki; Satoshi Sugiyama; Hiroshi Ogawa; Hiroko Kusimoto; Tatsuro Mutoh; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  J Neural Transm (Vienna)       Date:  2012-06-15       Impact factor: 3.575

3.  Measurement of the attachment and assembly of small amyloid-β oligomers on live cell membranes at physiological concentrations using single-molecule tools.

Authors:  Suman Nag; Jiji Chen; J Irudayaraj; S Maiti
Journal:  Biophys J       Date:  2010-09-22       Impact factor: 4.033

4.  Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.

Authors:  Victor L Villemagne; Keyla A Perez; Kerryn E Pike; W Mei Kok; Christopher C Rowe; Anthony R White; Pierrick Bourgeat; Olivier Salvado; Justin Bedo; Craig A Hutton; Noel G Faux; Colin L Masters; Kevin J Barnham
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 5.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

6.  Novel therapeutic approach for Alzheimer's disease by removing amyloid beta protein from the brain with an extracorporeal removal system.

Authors:  Kazunori Kawaguchi; Nobuya Kitaguchi; Shigeru Nakai; Kazutaka Murakami; Kunihiko Asakura; Tatsuro Mutoh; Yoshiro Fujita; Satoshi Sugiyama
Journal:  J Artif Organs       Date:  2010-02-23       Impact factor: 1.731

7.  Probing energetics of Abeta fibril elongation by molecular dynamics simulations.

Authors:  Takako Takeda; Dmitri K Klimov
Journal:  Biophys J       Date:  2009-06-03       Impact factor: 4.033

8.  Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Authors:  Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris
Journal:  Neurobiol Aging       Date:  2009-04-18       Impact factor: 4.673

9.  A causative link between the structure of aberrant protein oligomers and their toxicity.

Authors:  Silvia Campioni; Benedetta Mannini; Mariagioia Zampagni; Anna Pensalfini; Claudia Parrini; Elisa Evangelisti; Annalisa Relini; Massimo Stefani; Christopher M Dobson; Cristina Cecchi; Fabrizio Chiti
Journal:  Nat Chem Biol       Date:  2010-01-10       Impact factor: 15.040

10.  Role of aromatic side chains in amyloid β-protein aggregation.

Authors:  Risto Cukalevski; Barry Boland; Birgitta Frohm; Eva Thulin; Dominic Walsh; Sara Linse
Journal:  ACS Chem Neurosci       Date:  2012-09-24       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.